贝伐珠单抗联合参芪扶正注射液在晚期非鳞非小细胞肺癌老年患者中应用对生存质量的影响

Effect of bevacizumab combined with Shenqi Fuzheng Injection on quality of life in elderly patients with advanced non-squamous cell lung cancer

目的探讨贝伐珠单抗联合参芪扶正治疗晚期非鳞非小细胞肺癌老年患者对生存质量、肿瘤标志物和免疫功能的影响。方法选择我院2014年2月-2019年2月非鳞非小细胞肺癌老年患者152例,按治疗方法的不同分为对照组和观察组,各76例;其中对照组应用贝伐珠单抗治疗,观察组应用贝伐珠单抗联合参芪扶正注射液治疗,比较两组治疗后生存质量、肿瘤标志物和免疫功能。结果观察组治疗后肺癌治疗功能评估量表(FACT-L)评分高于对照组,糖类抗原-125(CA125)、细胞角蛋白19片段抗原(CYFRA21-1)和癌胚抗原(CEA)水平低于对照组,CD3^+、CD4^+和CD4^+/CD8^+水平高于对照组,以上差异均具有统计学意义(P<0.05)。结论贝伐珠单抗联合参芪扶正注射液治疗晚期非鳞非小细胞肺癌老年患者可有效降低肿瘤标志物水平,改善免疫功能,提高生存质量,推荐临床推广应用。

Objective To investigate the effect of bevacizumab combined with Shenqi Fuzheng on quality of life,tumor markers and immune function in elderly patients with advanced non-squamous cell lung cancer. Methods 152 elderly patients with NSCLC in our hospital from February 2014 to February 2019 were divided into control group and observation group according to different treatment methods, 76 cases in each group. The control group was treated with bevacizumab, while the observation group was treated with bevacizumab combined with Shenqi Fuzheng injection.The quality of life after treatment was compared between the two groups. Quantity, tumor markers and immune function. Results After treatment, the score of FACT-L in the observation group was higher than that in the control group, the levels of carbohydrate antigen-125(CA125), cytokeratin 19 fragment antigen(CYFRA21-1) and carcinoembryonic antigen(CEA) were lower than those in the control group, and the levels of CD3^+, CD4^+, CD4^+/CD8^+ were higher than those in the control group. The above differences were statistically significant.(P<0.05). Conclusion Bevacizumab combined with Shenqi Fuzheng injection can effectively reduce the level of tumor markers, improve immune function, improve the quality of life in elderly patients with advanced non-squamous cell lung cancer, and recommend clinical application.